Contineum Therapeutics (CTNM), which is developing therapies for multiple sclerosis and idiopathic pulmonary fibrosis, has filed for a proposed $150M initial public offering. The biotech company ...

The few developer orientated things i've been from microsoft are good, but if you have been keeping up with the information outside of these events, then there is nothing new. I can be good to see ...